Ironwood Pharmaceuticals raises 2026 guidance on LINZESS U.S. net sales growth
FROM THE WIRE · BUSINESSWIRE.COM
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn upward revision to full-year guidance at a small-cap biotech, relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Ironwood reported strong third-quarter 2026 results, its third consecutive strong quarter.
- 02Continued growth in U.S. LINZESS net sales drives the raised guidance.
- 03The company is focused on maximizing LINZESS, advancing apraglutide and sustaining profits.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets